We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-1.86%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$14.7B
AUM Growth
-$908M
Cap. Flow
-$379M
Cap. Flow %
-2.57%
Top 10 Hldgs %
84.38%
Holding
107
New
11
Increased
15
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$63.8M
2
ADPT icon
Adaptive Biotechnologies
ADPT
+$51.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$26M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$22.4M
5
HRTX icon
Heron Therapeutics
HRTX
+$20M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$184M
2
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$97.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$69.5M
4
GHDX
Genomic Health, Inc.
GHDX
+$55.6M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$38.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.63%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
51
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.03M 0.06%
97,484
+40,000
+70% +$2.79M
ALKS icon
52
Alkermes
ALKS
$8.15B
$9.02M 0.06%
400,000
+333,000
+497% +$9.13M
DERM
53
DELISTED
Dermira, Inc.
DERM
$8.67M 0.06%
906,943
– –
ALBO
54
DELISTED
Albireo Pharma Inc
ALBO
$8.06M 0.05%
250,000
– –
APLS
55
DELISTED
Apellis Pharmaceuticals
APLS
$7.95M 0.05%
313,725
– –
MIST icon
56
Milestone Pharmaceuticals
MIST
$131M
$7.24M 0.05%
+266,667
New +$5.5M
ANAB icon
57
AnaptysBio
ANAB
$1.54B
$6.38M 0.04%
113,086
– –
ABEO icon
58
Abeona Therapeutics
ABEO
$346M
$6.16M 0.04%
51,529
– –
HOOK
59
DELISTED
HOOKIPA Pharma
HOOK
$6.01M 0.04%
+89,286
New +$9.47M
ORTX
60
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$5.68M 0.04%
40,570
+28,070
+225% +$4.93M
HALO icon
61
Halozyme
HALO
$9.88B
$5.15M 0.04%
299,969
– –
BLUE
62
DELISTED
bluebird bio
BLUE
$5.09M 0.03%
3,088
– –
BLCM
63
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$4.55M 0.03%
267,782
– –
VYNE icon
64
VYNE Therapeutics
VYNE
$4.19M 0.03%
194
– –
GTHX
65
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.9M 0.03%
127,236
– –
NGM
66
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$3.66M 0.02%
+250,000
New +$3.66M
VKTX icon
67
Viking Therapeutics
VKTX
$3.87B
$3.53M 0.02%
425,000
– –
XLRN
68
DELISTED
Acceleron Pharma
XLRN
$3.45M 0.02%
83,900
– –
CRNX icon
69
Crinetics Pharmaceuticals
CRNX
$8.88B
$3.33M 0.02%
132,985
+1,735
+1% +$43K
LKFT
70
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$3.23M 0.02%
25,072
– –
ACHN
71
DELISTED
Achillion Pharmaceuticals
ACHN
$2.94M 0.02%
1,095,359
– –
ARAV
72
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.91M 0.02%
484,947
+54,062
+13% +$337K
XBIT icon
73
XBiotech
XBIT
$68.6M
$2.88M 0.02%
+380,442
New +$3.31M
HARP
74
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.79M 0.02%
21,429
– –
FTSV
75
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$2.65M 0.02%
250,000
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2019 Portfolio in Review

As of Q2 2019, Baker Bros. Advisors held 107 positions worth $14.7B, down 5.8% from $15.6B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors's Q2 2019 filing shows 11 new, 15 increased, 16 reduced and 4 closed positions. Its largest new stake was Atreca, Inc. Class A Common Stock: 3,532,760 shares worth $66.6M. The largest sale was Incyte, an estimated $184M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q2 2019 buy was Atreca, Inc. Class A Common Stock: 3,532,760 shares worth $66.6M.
  • Baker Bros. Advisors added most to Neurocrine Biosciences in Q2 2019, an estimated $26M increase.
  • Baker Bros. Advisors's biggest Q2 2019 reduction was Incyte, cutting an estimated $184M.
  • Baker Bros. Advisors fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $97.2M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $14.7B portfolio in Q2 2019.
  • Baker Bros. Advisors opened 11 new positions and closed 4 in Q2 2019.
  • Baker Bros. Advisors's portfolio value fell 5.8% quarter-over-quarter to $14.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.